intracranial infections after craniotomy
Conditions
Interventions
Tigecycline group:Tigecycline IV 100mgQ12h for 72 hours, and then evaluate the efficacy of treatment, if the treatment is not effctvie, change to combination of intracerebroventricular and intravenous
Sponsors
Department of Critical Care Medicine, Beijing Tiantan Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. After neurosurgery craniotomy; 2. diagnosed as intracranial infection; 3. Aged between 18 to 65 years; 4. Clinical doctors believe it is necessary to use the Tigecycline to treatment; 5. Have signed informed consent The diagnostic intracranial infection criteria was three of the following changes: (1) temperature higher than 38 or lower than 36, vomiting, headache, positive signs of meningeal irritation (nuchal rigidity, Brudzin ski's sign and Kernig's sign); (2) positive changes in CSF specimens: white blood cell (WBC) count more than 1000*10^6 cells/L, glucose less than 2.2 mmol/L or less than 40% of serum glucose; and (3) positive CSF cultures.
Exclusion criteria
Exclusion criteria: 1. Aged less than 18 or above 65; 2. Allergic history of any kind of tetracycline; 3. Severe cardiopulmonary, hepatic and renal insufficiency; 5. Maternal in the perinatal period; 6. Refused to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| drug concentrations of serum;drug concentrations of cerebrospinal fluid;CSF penetration of tigecycline;clinical effet of tigecycline; | — |
Secondary
| Measure | Time frame |
|---|---|
| security of tigecycline;Health Economics of tigecycline; | — |
Countries
China
Contacts
Public ContactWang Qiang
Outcome results
None listed